NasdaqGM:CRSPBiotechs
Is Now the Right Time for CRISPR Therapeutics After a 26.9% Pullback?
Wondering if CRISPR Therapeutics is a bargain or just a biotech buzzword? You are not alone. Many investors are asking the same question about whether now is the right time to get involved.
After an impressive 26.8% gain year-to-date and a respectable 11.2% return over the past year, the stock has pulled back sharply by 26.9% in the last 30 days. This shows how quickly sentiment can shift.
Much of this recent volatility has been driven by news around regulatory developments and fresh...